U.S. HIV/AIDS policy and funding should be guided by science, policy statement recommends

NewsGuard 100/100 Score

The IDSA Center for Global Health Policy and the HIV Medicine Association recently released a policy statement (.pdf) responding to the results of the HPTN 052 study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) at NIH, which found that people with HIV who received immediate antiretroviral therapy (ART) were more than 96 percent less likely to sexually transmit the infection to their uninfected partners. The statement provides recommendations for U.S. global and domestic AIDS policy and recommends that a larger share of the PEPFAR budget, up to 50 percent, be devoted to treatment; that HIV counseling and testing, including couples counseling, be expanded in all venues; and that PEPFAR prevention expenditures be evaluated based on evidence of efficacy of reducing HIV incidence, among other recommendations (9/9).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New report on HIV drug resistance: Challenges and recommendations